Are Wall Street Analysts Bullish on Agilent Technologies Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Should l Buy A?
Source: NASDAQ.COM
Company Overview and Performance: Agilent Technologies, valued at $38.5 billion, has underperformed the market with a 6.1% gain over the past year compared to the S&P 500's 32.1% increase, and is down 3.4% in 2024 against the SPX's 26.2% rise.
Analyst Ratings and Future Expectations: Despite recent Q4 results beating expectations, analysts project a decline in EPS for the current fiscal year; however, the consensus rating remains a "Moderate Buy" with price targets suggesting potential upside from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 116.640
Low
160.00
Averages
171.67
High
180.00
Current: 116.640
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilent to Acquire Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical for $950 million in cash, a deal expected to enhance Agilent's revenue growth rate and margin profile.
- Biocare's Performance: Since 2021, Biocare has achieved annual double-digit revenue and profit growth, generating over $90 million in revenue in 2025, bolstered by more than 300 specialized antibodies and strong R&D capabilities, thereby enhancing Agilent's pathology portfolio.
- Strategic Importance: Agilent's President and CEO Padraig McDonnell stated that this acquisition reflects the company's strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation, further solidifying its position in the life sciences and diagnostics markets.
- Transaction Timeline: The deal is expected to close by no later than Agilent's fourth fiscal quarter of 2026, at which point Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group, supporting the company's future business expansion.
See More
Agilent Acquires Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
- Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
- Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
- Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
See More
Agilent Acquires Biocare to Enhance Pathology Portfolio
- Biocare Acquisition: Agilent's $950 million acquisition of Biocare adds over 300 specialized antibodies and R&D capabilities, yet failed to revive investor sentiment, with shares slipping nearly 1% amid a broader market selloff.
- Financial Impact: Agilent anticipates that the acquisition will boost revenue growth and margins in the first year, with earnings per share expected to increase approximately 12 months post-closing, indicating strong long-term growth potential.
- Market Reaction: Agilent's Q1 earnings report showed $1.36 per share on $1.80 billion revenue, slightly below analyst expectations, prompting several brokerages to cut price targets while most maintained positive ratings on the stock.
- Retail Sentiment: Despite a 15% decline in stock price year-to-date, retail sentiment on Stocktwits remains 'bullish', reflecting confidence in Agilent's long-term prospects.
See More
Agilent Acquires Biocare Medical to Enhance Pathology Portfolio
- Acquisition Scale: Agilent has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, for $950 million, a transaction expected to significantly enhance Agilent's revenue and profit growth.
- Growth Potential: Biocare has achieved annual double-digit revenue and profit growth since 2021, with projected revenues exceeding $90 million in 2025, and the acquisition will further strengthen Agilent's competitive position in the pathology market.
- Strategic Synergies: This acquisition will integrate Agilent's global operations with Biocare's strong U.S. commercial presence, creating a more robust platform to meet diverse research and clinical customer needs while accelerating new product development.
- Financial Benefit Expectations: The transaction is expected to positively impact Agilent's top-line growth rate, margin profile, and non-instrument revenue mix in the first year, with an anticipated accretive effect on earnings per share approximately 12 months post-close.
See More
Agilent to Acquire Biocare for $950 Million
- Acquisition Overview: Agilent Technologies has announced its acquisition of Biocare for $950 million in cash, marking a strategic expansion in the life sciences and diagnostics sector, which is expected to enhance its competitiveness in the cancer diagnostics market.
- Biocare's Growth Journey: Under the stewardship of Excellere Partners and GHO Capital, Biocare has achieved annual double-digit revenue and profit growth since 2021, strengthening its core immunohistochemistry business while expanding into molecular diagnostics, showcasing its strong market potential.
- Strategic Synergies: This acquisition will enable Biocare to complement Agilent's capabilities, with both companies' expertise in cancer diagnostics fostering innovation and improved service levels, ultimately providing higher quality solutions for customers.
- Future Outlook: Biocare's CEO, Luis de Luzuriaga, stated that the acquisition will accelerate the company's innovation process and enhance service quality, ultimately benefiting patients, reflecting a shared commitment to product quality and clinical impact between the two organizations.
See More
AGILENT TECHNOLOGIES INC: UBS Lowers Price Target to $165 from $180
Company Overview: Agile Technologies is involved in the tech sector, focusing on innovative solutions and products.
Stock Price Update: The target price for Agile Technologies has been adjusted to $165, down from the previous $180.
See More
Agilent to Acquire Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical for $950 million in cash, a deal expected to enhance Agilent's revenue growth rate and margin profile.
- Biocare's Performance: Since 2021, Biocare has achieved annual double-digit revenue and profit growth, generating over $90 million in revenue in 2025, bolstered by more than 300 specialized antibodies and strong R&D capabilities, thereby enhancing Agilent's pathology portfolio.
- Strategic Importance: Agilent's President and CEO Padraig McDonnell stated that this acquisition reflects the company's strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation, further solidifying its position in the life sciences and diagnostics markets.
- Transaction Timeline: The deal is expected to close by no later than Agilent's fourth fiscal quarter of 2026, at which point Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group, supporting the company's future business expansion.
See More
Agilent Acquires Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
- Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
- Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
- Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
See More
Agilent Acquires Biocare to Enhance Pathology Portfolio
- Biocare Acquisition: Agilent's $950 million acquisition of Biocare adds over 300 specialized antibodies and R&D capabilities, yet failed to revive investor sentiment, with shares slipping nearly 1% amid a broader market selloff.
- Financial Impact: Agilent anticipates that the acquisition will boost revenue growth and margins in the first year, with earnings per share expected to increase approximately 12 months post-closing, indicating strong long-term growth potential.
- Market Reaction: Agilent's Q1 earnings report showed $1.36 per share on $1.80 billion revenue, slightly below analyst expectations, prompting several brokerages to cut price targets while most maintained positive ratings on the stock.
- Retail Sentiment: Despite a 15% decline in stock price year-to-date, retail sentiment on Stocktwits remains 'bullish', reflecting confidence in Agilent's long-term prospects.
See More
Agilent Acquires Biocare Medical to Enhance Pathology Portfolio
- Acquisition Scale: Agilent has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, for $950 million, a transaction expected to significantly enhance Agilent's revenue and profit growth.
- Growth Potential: Biocare has achieved annual double-digit revenue and profit growth since 2021, with projected revenues exceeding $90 million in 2025, and the acquisition will further strengthen Agilent's competitive position in the pathology market.
- Strategic Synergies: This acquisition will integrate Agilent's global operations with Biocare's strong U.S. commercial presence, creating a more robust platform to meet diverse research and clinical customer needs while accelerating new product development.
- Financial Benefit Expectations: The transaction is expected to positively impact Agilent's top-line growth rate, margin profile, and non-instrument revenue mix in the first year, with an anticipated accretive effect on earnings per share approximately 12 months post-close.
See More
Agilent to Acquire Biocare for $950 Million
- Acquisition Overview: Agilent Technologies has announced its acquisition of Biocare for $950 million in cash, marking a strategic expansion in the life sciences and diagnostics sector, which is expected to enhance its competitiveness in the cancer diagnostics market.
- Biocare's Growth Journey: Under the stewardship of Excellere Partners and GHO Capital, Biocare has achieved annual double-digit revenue and profit growth since 2021, strengthening its core immunohistochemistry business while expanding into molecular diagnostics, showcasing its strong market potential.
- Strategic Synergies: This acquisition will enable Biocare to complement Agilent's capabilities, with both companies' expertise in cancer diagnostics fostering innovation and improved service levels, ultimately providing higher quality solutions for customers.
- Future Outlook: Biocare's CEO, Luis de Luzuriaga, stated that the acquisition will accelerate the company's innovation process and enhance service quality, ultimately benefiting patients, reflecting a shared commitment to product quality and clinical impact between the two organizations.
See More
AGILENT TECHNOLOGIES INC: UBS Lowers Price Target to $165 from $180
Company Overview: Agile Technologies is involved in the tech sector, focusing on innovative solutions and products.
Stock Price Update: The target price for Agile Technologies has been adjusted to $165, down from the previous $180.
See More
